Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral small-molecule GLP-1 therapy, backed by an oversubscribed $100 million series B round.
- Home |
- Obesity biotech Ambrosia scores $100M series B to to take next-gen oral GLP-1 into the clinic
Obesity biotech Ambrosia scores $100M series B to to take next-gen oral GLP-1 into the clinic
- March 31, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
